In Brief

Novartis makes OTC exec change following recall and plant shutdown; Prestige Brands adopts plan to deter Genomma takeover bid; Pfizer scoops up Emergen-C maker Alacer; CSPI threatens Amway with Nutrilite suit; more news In Brief.

Novartis AG names Brian McNamara to replace departing OTC division head Naomi Kelman as the company attempts to recover from a recall and plant shutdown in the consumer health division. McNamara took over Feb. 29 as division head of Novartis OTC, which has a seat on the Swiss firm’s executive committee. He joined Novartis in 2004 after 16 years at Procter & Gamble Co., and has served as Novartis’ OTC region head in both Europe and the Americas. Kelman’s tenure at Novartis lasted just under a year; she left a leadership role at Johnson & Johnson’s diabetes care business for Novartis in March 2011, just as the company was realigning to emphasize the importance of the consumer business Also see "Novartis Makes Room For OTC Division Head On Executive Committee" - Pink Sheet, 21 February, 2011.. McNamara takes the reins of a division attempting to get its Lincoln, Neb., facility back online by mid-year after FDA inspectors found persistent quality control problems and the firm recalled Excedrin and other OTCs Also see "FDA Pressure Likely In Novartis OTC Plant Shutdown, Recalls" - Pink Sheet, 6 February, 2012..

Prestige Brands Holdings Inc.’s board of directors adopts a stockholder rights plan to discourage a hostile takeover bid from...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from United States

Ultragenyx Says CRL Discussions ‘Productive’ Despite US FDA Leadership Upheaval

 

Ultragenyx said talks with the FDA about a path forward after receiving a CRL for UX111 have been productive despite the recent upheaval at the agency.

Prasad 2.0 Brings New Instability Concerns, Questions About Changed Regulatory Philosophy

 

Many agency stakeholders believe Vinay Prasad may be forced to change his regulatory approach at least somewhat after receiving a second chance to lead the US FDA's biologics center.

More Telework, More Staff, US FDA’s Tidmarsh Plans To Alleviate Workforce Challenges

 

The new CDER director focused on plans to improve morale during an Aug. 8 townhall, but staff comments indicate that may be a challenge.

US Pricing Reform: New Products Offer ‘On Ramp’ To Implementation, Lilly’s Ricks Says

 
• By 

Eli Lilly's CEO argued that pricing reforms aimed at existing drugs would be “hard to sustain or justify,” while other companies suggested a growing interest in direct-to-consumer sales programs.

More from North America

New US FDA CDER Director Pledges No Politics In Approvals, Adds Higher Ups Can Overturn

 

New CDER Director George Tidmarsh promised to keep politics out of drug approvals, but suggested during a meeting with staff that he could not insulate the drug center from political pressures coming from those above him.

EU Must Up Competitiveness To Counter US Tariffs And Pricing Woes For SMEs

 

Companies in Europe cannot delay business decision making much longer to wait for more certainty on major US policy shifts on tariffs and pricing.

HHS mRNA Vaccine Funding Cut Impact Limited (And One Contract Isn’t Even mRNA)

 

HHS' culling of mRNA vaccine projects under BARDA will heavily impact pandemic preparedness. Tiba Biotech was even “caught off guard” by its inclusion, because its project was neither a vaccine nor mRNA-based.